Antivirals for COVID-19: A critical review
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
No specific drugs have been approved for coronavirus disease 2019 (COVID-19) to date as the development of antivirals usually requires time. Therefore, assessment and use of currently available antiviral drugs is critical for a timely response to the current pandemic. Here, we have reviewed anti-SARS-CoV-2 potencies of available antiviral drug groups such as fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion-channel protein blockers. Although clinical trials to assess the efficacy of these antivirals are ongoing, this review highlights important information including docking and modeling analyses, in vitro studies, as well as results from clinical uses of these antivirals against COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · cited 1×
“An in vitro study reported that a combination of remdesivir and chloroquine, an anti-malarial drug, effectively inhibited SARS-CoV-2 growth in Vero E6 cells.(108) Clinical trials are ongoing to assess the efficacy of remdesivir for COVID-19 in the US,(109) Norway,(110) and France.”
BackgroundYang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661 · cited 1×
“The virus uses S protein to neutralize antibodies, making it easier to bind to the host receptors.(31) Although the detailed fusion machinery of SARS-CoV-2 is not fully understood, Betacoronavirus mostly use hemagglutinin-esterase (HE) to link to sialic acid on the glycoprotein surface.”
BackgroundClinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101623 · Cited by 2,542 · cited 2×
“Rapid assessment of the currently available antiviral drugs to be used for COVID-19 patients is therefore crucial in this time of crisis as well as discovering newer drugs.(5,19) Since the virus hijacks the host system via attaching to and then penetrating the host cells, fol-”
BackgroundMethodSelf-citationCOVID-19: immunopathology and its implications for therapy
Cao, X. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0308-3 · Cited by 1,609
Cited by
A review: Mechanism of action of antiviral drugs
Kausar, S., Said Khan, F., Ishaq Mujeeb Ur Rehman, M., Akram, M., Riaz, M., Rasool, G., Hamid Khan, A., Saleem, I., Shamim, S., & Malik, A. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211002621 · Cited by 429
Myths and conspiracy theories on vaccines and COVID-19: Potential effect on global vaccine refusals
Ullah, I., Khan, K. S., Tahir, M. J., Ahmed, A., & Harapan, H. (2021) · Vacunas · doi:10.1016/j.vacun.2021.01.001 · Cited by 302
Self-citationBaricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials
Selvaraj, V., Finn, A., Lal, A., Khan, M. S., Dapaah-Afriyie, K., & Carino, G. P. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101489 · Cited by 101
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Metadata
- Authors
- Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K., & Harapan, H.
- Venue
- Clinical Epidemiology and Global Health
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 9
- Pages
- 90-98
- ISSN
- 2213-3984 (ISSN-L)
- OpenAlex
- W3046074789
- Cited by
- 185
- References
- 17
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antivirals for COVID-19: A critical review. https://app.cochat.ai/papers/10.1016/j.cegh.2020.07.006
- The paper
- Frediansyah, A., Tiwari, R., Sharun, K., Dhama, K., & Harapan, H. (2021). Antivirals for COVID-19: A critical review. Clinical Epidemiology and Global Health. https://doi.org/10.1016/j.cegh.2020.07.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.